CAR-T (Solid Tumor) Deal Benchmarks in Oncology

Median Upfront

$356M

Range: $197M - $506M

Total Deal Value

$2.3B

Range: $1.5B - $3.1B

Royalty Rate

13% - 21.3%

Tiered up to 25.3%

Dev Milestones

$484M

Range: $323M - $647M

Model Your Deal

Market Analysis

CAR-T (Solid Tumor) therapies in oncology have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 car-t (solid tumor) asset in oncology is $356M, with total deal values reaching $2.3B. Development milestones average $484M, while regulatory milestones contribute $774M.

The oncology car-t (solid tumor) landscape is characterized by high competitive intensity with numerous active programs and a rapidly evolving standard of care. ADCs, bispecifics, and radiopharmaceuticals continue to drive premium valuations across solid and hematologic tumors. The recommended deal structure allocates approximately 16% to upfront payments and 84% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for car-t (solid tumor) oncology deals range from 13% to 21.3% at the base tier, with tiered escalation reaching 17%-25.3% on blockbuster sales. Commercial milestones averaging $678M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a car-t (solid tumor) oncology licensing deal?

Based on our analysis, Phase 2 car-t (solid tumor) licensing deals in oncology average $356M in upfront payments, with a range of $197M to $506M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for car-t (solid tumor) oncology transactions?

The median total deal value for Phase 2 car-t (solid tumor) assets in oncology is $2.3B, ranging from $1.5B to $3.1B. This includes development milestones ($484M), regulatory milestones ($774M), and commercial milestones ($678M).

What royalty rates are standard for car-t (solid tumor) deals in oncology?

Base royalty rates for car-t (solid tumor) oncology transactions range from 13% to 21.3%, with tiered escalations reaching 17%-25.3% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in car-t (solid tumor) oncology deals?

CAR-T (Solid Tumor) oncology deals allocate approximately 84% of total deal value to milestones. Development milestones ($484M) make up the largest share, followed by commercial milestones ($678M) and regulatory milestones ($774M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

Small Molecule in Oncology

View

Monoclonal Antibody in Oncology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating